Matias Valsecchi is an Oncology physician affiliated with Marshall University. OpenAlex indexes 64 publications with 2,663 citations (h-index 18).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
26.4%Aromatase Inhibitor13.4%Anastrozole100%Part D≥55 patientsThalidomide Analog4.1%Lenalidomide79%Revlimid21%Part D<11 patients+ 4 more classes in this area
Nervous system
24.7%Opioid Agonist8.2%Tramadol Hcl42%Oxycodone Hcl35%Fentanyl23%Part D<11 patientsPhenothiazine5.8%Prochlorperazine Maleate100%Part D≥41 patients+ 4 more classes in this area
Metabolism & gastrointestinal
20.3%Corticosteroid6.3%Prednisone100%Part D≥33 patientsSerotonin-3 Receptor Antagonist6%Ondansetron Odt66%Ondansetron Hcl34%Part D≥42 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A randomized phase II study of adjuvant sunitinib or valproic acid in high-risk patients with uveal melanoma.
Journal of Clinical Oncology
2020 - Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?
Reviews on Recent Clinical Trials
2016
Similar KOLs
Other experts from the same institution or the same specialty.
David Gozal, MD
Marshall University
Khalid Abozguia, MD, PhD
Marshall University
James Gigantelli, MD
Marshall University
Zeid Khitan, MD
Marshall University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”